Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SKELAXIN vs CARISOPRODOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Skelaxin (metaxalone) is a centrally acting skeletal muscle relaxant. Its exact mechanism of action is not fully understood, but it is believed to act primarily by depressing the central nervous system (CNS) through inhibition of polysynaptic reflexes at the spinal and supraspinal levels, leading to muscle relaxation without directly affecting the neuromuscular junction or muscle fibers.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
FDA-approved: Adjunctive treatment for acute, painful musculoskeletal conditions (muscle spasms) associated with strains, sprains, and other muscle injuries.,Off-label: Chronic low back pain, fibromyalgia, tension headaches, cerebral palsy, multiple sclerosis (adjunctive).
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
800 mg orally three to four times daily.
250-350 mg orally 3 times daily and at bedtime
1-2 hours (terminal elimination half-life); clinical context: short duration of action, requires multiple daily dosing
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Metaxalone is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP1A2 and to a lesser extent CYP2D6, CYP2E1, and CYP3A4. It undergoes oxidative metabolism and glucuronidation. The major metabolites are hydroxylated derivatives and their glucuronide conjugates, which are inactive.
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Primarily renal (approximately 99% as unchanged drug); <1% fecal
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
75-80% bound, primarily to albumin
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
Vd/F ~ 1.5 L/kg; indicates extensive tissue distribution
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
Oral: 25-30% (due to first-pass metabolism)
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to risk of accumulation.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class A, B, or C.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not recommended for pediatric patients due to lack of safety and efficacy data.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
Initiate at lower doses (e.g., 400 mg three to four times daily) due to increased sensitivity and risk of adverse effects; monitor closely.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
None
None
Central nervous system depression (sedation, dizziness, drowsiness); may impair ability to drive or operate machinery. Concomitant use with alcohol or other CNS depressants may enhance effects. Hepatotoxicity (rare but serious; monitor liver enzymes in patients with pre-existing liver disease). Serotonin syndrome risk when used with other serotonergic drugs. Risk of abuse and dependence (less than benzodiazepines, but caution in substance abuse history). Photosensitivity (avoid prolonged sun exposure).
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
Absolute: Known hypersensitivity to metaxalone or any component; significantly impaired renal or hepatic function; history of drug-induced hemolytic anemia or other blood dyscrasias. Relative: Severe hepatic impairment; caution in patients with pre-existing liver disease, renal impairment, or older adults. Pregnancy (Category C; use only if benefit outweighs risk). Lactation (not recommended). Pediatric use (<12 years: safety not established).
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
Taking with food, especially high-fat meals, may increase absorption and risk of side effects. Avoid alcohol, as it increases CNS depression. No specific foods to avoid, but maintain consistent intake timing relative to meals.
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
Risk summary: Not known to increase risk of major birth defects; limited human data. First trimester: No increased risk reported; animal studies show no teratogenicity. Second and third trimesters: No specific risks documented but should be used only if clearly needed. Fetal effects: Potential for muscle relaxation, but no clear adverse outcomes.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
Present in human milk; M/P ratio unknown. Limited data suggest no adverse effects in breastfed infants; caution advised. Use only if benefit outweighs risk.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
No dose adjustment recommended; pharmacokinetic changes in pregnancy not well studied. Use lowest effective dose for shortest duration.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
Skelaxin (metaxalone) is a centrally acting muscle relaxant indicated for acute musculoskeletal pain. Onset is about 1 hour with a duration of 4-6 hours. Drowsiness is the most common side effect; avoid concurrent use with alcohol or other CNS depressants. Not recommended in patients with significant hepatic impairment due to extensive hepatic metabolism. Tablets should be taken with food to reduce GI upset, but high-fat meals can increase Cmax and AUC.
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or hazardous activities until you know how you react.,Avoid alcohol while taking this medication.,Take with food or milk to prevent stomach upset.,Do not stop suddenly; follow doctor's instructions for discontinuation.,Report any signs of liver problems (yellowing skin/eyes, dark urine, persistent nausea) to your doctor immediately.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SKELAXIN vs CARISOPRODOL, answered by our medical review team.
SKELAXIN is a Skeletal muscle relaxant that works by Skelaxin (metaxalone) is a centrally acting skeletal muscle relaxant. Its exact mechanism of action is not fully understood, but it is believed to act primarily by depressing the central nervous system (CNS) through inhibition of polysynaptic reflexes at the spinal and supraspinal levels, leading to muscle relaxation without directly affecting the neuromuscular junction or muscle fibers.. CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SKELAXIN and CARISOPRODOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SKELAXIN is: 800 mg orally three to four times daily.. The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SKELAXIN and CARISOPRODOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SKELAXIN is classified as Category C. Risk summary: Not known to increase risk of major birth defects; limited human data. First trimester: No increased risk reported; animal studies show no teratogenicity. Second and . CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.